US FDA Tried, But Failed, To Take Compounding Issue Off The Table At Makena AdComm
Executive Summary
Clinicians and patients would look for 17P wherever they could find it if AMAG’s FDA-approved formulation of the preterm birth drug comes off the market, panelists said; Cowen analysts believe the potential for safety concerns posed by compounded formulations will save Makena from the regulatory chopping block.
You may also be interested in...
Makena Enforcement Discretion, Compounding Still In Limbo Post Long-Awaited Withdrawal
US FDA Commissioner and Chief Scientist call for immediate withdrawal of the preterm birth prevention drug and generic versions but defer to the Center for Drug Evaluation and Research on how to implement key lingering details.
A Conspicuous Absence: Professional Societies ACOG, SMFM Missing From Makena Public Hearing
The American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine did not testify at the public hearing on CDER’s proposal to withdraw the preterm birth prevention drug, even though the groups’ clinical guidelines still recommend use of Makena and its active ingredient.
FDA Requests Withdrawal Of Makena And Generics
Preterm birth prevention drug should come off the market to ensure the accelerated approval pathway does not operate as a lower approval standard, agency says; proposed withdrawal comes almost a year after an advisory committee split on the question of whether Makena should stay on the market in light of delayed, and ultimately unsuccessful, confirmatory study.